<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732940</url>
  </required_header>
  <id_info>
    <org_study_id>HGS1006-1070</org_study_id>
    <secondary_id>112232</secondary_id>
    <nct_id>NCT00732940</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-Bâ„¢), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Human Genome Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Human Genome Sciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and tolerability of repeated subcutaneous
      (SC) doses of belimumab in subjects with SLE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will evaluate the safety, pharmacokinetics (PK), and effect on biomarkers
      of repeated subcutaneous (SC) administration of belimumab in subjects with SLE. As data
      permit, an exploratory pharmacodynamic analysis will be performed to evaluate the correlation
      between belimumab serum exposure, PGA, SELENA SELDAI, and biomarker effects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated study for business reasons.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the Number of Participants Who Experienced Adverse Events (AEs) During the 24 Week Period.</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>SEE ALSO ADVERSE EVENTS RESULTS SECTION</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in CD20+ (Total) B Cells at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Percent Change From Baseline in CD20+ (Total) B Cells at Week 24.</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in CD20+/CD27- (Naive) B Cells at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Percent Change From Baseline in CD20+/CD27-(Naive) B Cells at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Percent Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Percent Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Belimumab Concentration Levels (Pharmacokinetic [PK]) Over 24 Weeks.</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in IgA at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in IgA at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in IgG at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in IgG at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in IgM at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in IgM at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Physician's Global Assessment (PGA) Score at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in PGA Score at Week 24.</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in the Safety of Estrogen in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in the SELENA SLEDAI Score at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Complement C3 at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in Compliment C3 at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Complement C4 at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in Complement C4 at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Anti-Double-Stranded DNA (Anti-dsDNA)at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in Anti-dsDNA at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in High Density Lipoproteins (HDL) at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in HDL at Week 24</measure>
    <time_frame>Baseline, 24 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Total Cholesterol at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in Total Cholesterol at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change From Baseline in Triglycerides at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Triglycerides at Week 24</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Belimumab Q2WKS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every other week: 100 mg of belimumab (1 injection) subcutaneous (under the skin) on days 0, 7, and 14, then every other week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belimumab 3X/WK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three times weekly: 200 mg of belimumab (2 injections of 100 mg each) subcutaneous (under the skin) on days 0, 2, and 4 then 100 mg three times a week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab 100 mg SC</intervention_name>
    <description>Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.</description>
    <arm_group_label>Belimumab Q2WKS</arm_group_label>
    <other_name>LymphoStat-Bâ„¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab 100 mg SC</intervention_name>
    <description>Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.</description>
    <arm_group_label>Belimumab 3X/WK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria

          -  Active SLE disease

          -  On stable SLE treatment regimen

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Have received treatment with an B cell targeted therapy

          -  Have received treatment with a biologic investigational agent in the past year

          -  Have received intravenous (IV) cyclophosphamide within 180 days of Day 0

          -  Have severe lupus kidney disease

          -  Have active central nervous system (CNS) lupus

          -  Have required management of acute or chronic infections with the past 60 days

          -  Have current drug or alcohol abuse or dependence or within the past year

          -  Have a historically positive test or test positive at screening for human
             immunodeficiency virus (HIV), hepatitis B, or hepatitis C

          -  Have a history of an allergic or anaphylactic reaction to drugs, food, or insects
             requiring medical intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-7201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valerious Medical Group Research Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Medical Group, PA</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiechtner Research, Inc.</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Health System/Rheumatology, Allergy, Immunology</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Center for Arthritis Therapy &amp; Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central &quot;Igancio Morones Prieto&quot;</name>
      <address>
        <city>San Lusi Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <results_first_submitted>April 7, 2011</results_first_submitted>
  <results_first_submitted_qc>April 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2011</results_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>Lupus</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Belimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Belimumab SC Q2WKS</title>
          <description>100 mg of belimumab (1 subcutaneous injection) on days 0, 7, and 14, then every other week until Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.</description>
        </group>
        <group group_id="P2">
          <title>Belimumab SC 3X/WK</title>
          <description>200 mg of belimumab (2 subcutaneous injections of 100 mg each) on days 0, 2, and 4 then 100 mg three times a week until Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Belimumab SC Q2WKS</title>
        </group>
        <group group_id="B2">
          <title>Belimumab SC 3X/WK</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="11.5"/>
                    <measurement group_id="B2" value="40.9" spread="13.1"/>
                    <measurement group_id="B3" value="40.1" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of the Number of Participants Who Experienced Adverse Events (AEs) During the 24 Week Period.</title>
        <description>SEE ALSO ADVERSE EVENTS RESULTS SECTION</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Please see Adverse Events Section</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Number of Participants Who Experienced Adverse Events (AEs) During the 24 Week Period.</title>
          <description>SEE ALSO ADVERSE EVENTS RESULTS SECTION</description>
          <population>Please see Adverse Events Section</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent of patients with at least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3"/>
                    <measurement group_id="O2" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent of patients with at least 1 Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent of patients with an AE resulting in death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Belimumab Concentration Levels (Pharmacokinetic [PK]) Over 24 Weeks.</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Belimumab Concentration Levels (Pharmacokinetic [PK]) Over 24 Weeks.</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Âµg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="11.6"/>
                    <measurement group_id="O2" value="120.8" spread="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in IgA at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in IgA at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.08"/>
                    <measurement group_id="O2" value="-0.3" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in IgA at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in IgA at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" lower_limit="-45.1" upper_limit="15.4"/>
                    <measurement group_id="O2" value="-10.7" lower_limit="-36.4" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in IgG at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in IgG at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.7"/>
                    <measurement group_id="O2" value="-1.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in IgG at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in IgG at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" lower_limit="-47.0" upper_limit="12.1"/>
                    <measurement group_id="O2" value="-9.5" lower_limit="-42.9" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in IgM at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in IgM at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.04"/>
                    <measurement group_id="O2" value="-0.4" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in IgM at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in IgM at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.6" lower_limit="-80.0" upper_limit="11.0"/>
                    <measurement group_id="O2" value="-26.9" lower_limit="-71.6" upper_limit="170.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in CD20+ (Total) B Cells at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in CD20+ (Total) B Cells at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.5" spread="20.4"/>
                    <measurement group_id="O2" value="-75.3" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Percent Change From Baseline in CD20+ (Total) B Cells at Week 24.</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in CD20+ (Total) B Cells at Week 24.</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.5" spread="8.88" lower_limit="-86.3" upper_limit="55.2"/>
                    <measurement group_id="O2" value="-38.2" spread="13.26" lower_limit="-86.3" upper_limit="130.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in CD20+/CD27- (Naive) B Cells at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in CD20+/CD27- (Naive) B Cells at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.9" spread="18.5"/>
                    <measurement group_id="O2" value="-95.0" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Percent Change From Baseline in CD20+/CD27-(Naive) B Cells at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in CD20+/CD27-(Naive) B Cells at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.9" spread="6.47" lower_limit="-89.6" upper_limit="4.8"/>
                    <measurement group_id="O2" value="-66.7" spread="8.0" lower_limit="-90.2" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>cells/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100.3" spread="389.8"/>
                    <measurement group_id="O2" value="-77.2" spread="456.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Percent Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in CD20+/CD69+ (Activated) B Cells at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="-69.6" upper_limit="1496.3"/>
                    <measurement group_id="O2" value="10.2" lower_limit="-87.0" upper_limit="779.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="6.0"/>
                    <measurement group_id="O2" value="19.6" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Percent Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in CD20+/CD27+ (Memory) B Cells at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="-37.5" upper_limit="288.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="-45.5" upper_limit="600.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Physician's Global Assessment (PGA) Score at Week 24</title>
        <description>PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.</description>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Physician's Global Assessment (PGA) Score at Week 24</title>
          <description>PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.</description>
          <population>Last Observation Carried Forward (LOCF)</population>
          <units>Scores on a 3-point scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.09"/>
                    <measurement group_id="O2" value="-0.4" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in PGA Score at Week 24.</title>
        <description>The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in PGA Score at Week 24.</title>
          <description>The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.</description>
          <population>LOCF</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.1" spread="6.6"/>
                    <measurement group_id="O2" value="-24.8" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in the Safety of Estrogen in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24</title>
        <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare.</description>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in the Safety of Estrogen in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24</title>
          <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare.</description>
          <population>LOCF</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="0.8"/>
                    <measurement group_id="O2" value="-3.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in the SELENA SLEDAI Score at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in the SELENA SLEDAI Score at Week 24</title>
          <population>LOCF</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.8" spread="9.1"/>
                    <measurement group_id="O2" value="-40.5" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Complement C3 at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes only patients with low C3 (&lt;900 mg/L) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Complement C3 at Week 24</title>
          <population>Analysis population includes only patients with low C3 (&lt;900 mg/L) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.0" spread="51.5"/>
                    <measurement group_id="O2" value="4.0" spread="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in Compliment C3 at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes only patients with low C3 (&lt;900 mg/L) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in Compliment C3 at Week 24</title>
          <population>Analysis population includes only patients with low C3 (&lt;900 mg/L) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="13.6" upper_limit="55.4"/>
                    <measurement group_id="O2" value="3.6" lower_limit="-25.7" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Complement C4 at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes only patients with low C4 (&lt;16 mg/dL) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Complement C4 at Week 24</title>
          <population>Analysis population includes only patients with low C4 (&lt;16 mg/dL) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.7"/>
                    <measurement group_id="O2" value="2.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in Complement C4 at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes only patients with low C4 (&lt;16 mg/dL) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in Complement C4 at Week 24</title>
          <population>Analysis population includes only patients with low C4 (&lt;16 mg/dL) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="0" upper_limit="133.3"/>
                    <measurement group_id="O2" value="40.0" lower_limit="-46.7" upper_limit="200.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Anti-Double-Stranded DNA (Anti-dsDNA)at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes only patients positive for anti-dsDNA (â‰¥30 IU/mL) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Anti-Double-Stranded DNA (Anti-dsDNA)at Week 24</title>
          <population>Analysis population includes only patients positive for anti-dsDNA (â‰¥30 IU/mL) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="11.1"/>
                    <measurement group_id="O2" value="-6.0" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in Anti-dsDNA at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes only patients positive for anti-dsDNA (â‰¥30 IU/mL) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in Anti-dsDNA at Week 24</title>
          <population>Analysis population includes only patients positive for anti-dsDNA (â‰¥30 IU/mL) at baseline and must have had a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" lower_limit="-51.4" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-57.2" upper_limit="125.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in High Density Lipoproteins (HDL) at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in High Density Lipoproteins (HDL) at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.04"/>
                    <measurement group_id="O2" value="0.0" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in HDL at Week 24</title>
        <time_frame>Baseline, 24 week</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in HDL at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="-16.1" upper_limit="34.6"/>
                    <measurement group_id="O2" value="2.2" lower_limit="-38.2" upper_limit="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Total Cholesterol at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Total Cholesterol at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.09"/>
                    <measurement group_id="O2" value="0.0" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in Total Cholesterol at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in Total Cholesterol at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-17.2" upper_limit="20.9"/>
                    <measurement group_id="O2" value="1.6" lower_limit="-36.3" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change From Baseline in Triglycerides at Week 24</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in Triglycerides at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" lower_limit="-46.9" upper_limit="183.0"/>
                    <measurement group_id="O2" value="4.5" lower_limit="-59.4" upper_limit="120.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Triglycerides at Week 24</title>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab SC Q2WKS</title>
          </group>
          <group group_id="O2">
            <title>Belimumab SC 3X/WK</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Triglycerides at Week 24</title>
          <population>Analysis population includes all patients with both a baseline and Week 24 laboratory sample.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.14"/>
                    <measurement group_id="O2" value="-0.0" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Belimumab SC Q2WKS</title>
          <description>The Q2wk group will receive 100 mg of belimumab (1 injection) plus standard therapy on Days 0, 7, 14, and then every 2 weeks thereafter.</description>
        </group>
        <group group_id="E2">
          <title>Belimumab SC 3X/WK</title>
          <description>The 3x/wk group will receive 200 mg of belimumab (2 injections of 100 mg each) plus standard therapy on Days 0, 2, and 4 and then 100 mg (1 injection) 3 times per week thereafter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>SLE arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For multi-center trials,no investigator will be authorized to publish study results from an individual center until the earlier of the multi-center trial results are published or 12 months after the end or termination of the multi-center trial at all sites. All manuscripts and abstracts must be submitted to the sponsor for review least 30 days prior to submission for publication or for presentation at a scientific meeting. The sponsor may delay publication for up to 3 months if indicated.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

